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Abstract
Acquired drug resistance represents a frequent obstacle which hampers efficient chemotherapy of cancers. The
contribution of aberrant DNA methylation to the development of drug resistant tumor cells has gained increasing attention
over the past decades. Hence, the objective of the presented study was to characterize DNA methylation changes which
arise from treatment of tumor cells with the chemotherapeutic drug doxorubicin. DNA methylation levels from CpG islands
(CGIs) linked to twenty-eight genes, whose expression levels had previously been shown to contribute to resistance against
DNA double strand break inducing drugs or tumor progression in different cancer types were analyzed. High-definition DNA
methylation profiles which consisted of methylation levels from 800 CpG sites mapping to CGIs around the transcription
start sites of the selected genes were determined. In order to investigate the influence of CGI methylation on the expression
of associated genes, their mRNA levels were investigated via qRT-PCR. It was shown that the employed method is suitable
for providing highly accurate methylation profiles, comparable to those obtained via clone sequencing, the gold standard
for high-definition DNA methylation studies. In breast carcinoma cells with acquired resistance against the double strand
break inducing drug doxorubicin, changes in methylation of specific cytosines from CGIs linked to thirteen genes were
detected. Moreover, similarities between methylation profiles obtained from breast and ovarian carcinoma cell lines with
acquired doxorubicin resistance were found. The expression levels of a subset of analyzed genes were shown to be linked to
the methylation levels of the analyzed CGIs. Our results provide detailed DNA methylation information from two separate
model systems for acquired doxorubicin resistance and suggest the occurrence of similar methylation changes in both
systems upon exposure to the drug.
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Introduction
This study was designed to investigate epigenetic alterations
which arise from treatment of tumor cells with the anthracycline
antibiotic, doxorubicin [1]. Early stage and metastatic breast
cancer, as well as platinum-refractory/-resistant ovarian cancer is
commonly treated by means of liposomal doxorubicin either as
monotherapy or in combination with other chemotherapeutic
drugs [2,3]. Acquired resistance, however, frequently prevents
successful doxorubicin treatment of those diseases. Epigenetic
alterations are potential driving forces for acquired chemoresis-
tance [4]. A typical epigenetic modification, which is frequently
observed in tumor cells, is aberrant methylation of cytosine bases
(C) located 59 of a guanine base (G), so called CpG dinucleotides
[5]. Although CpG dinucleotides are generally underrepresented
in mammalian genomes, they frequently cluster around the
transcription start site (TSS) of genes, in genomic areas referred
to as CpG islands (CGIs) [6]. Genome-wide hypo-methylation, in
combination with CGI specific hyper-methylation, is a common
hallmark of cancer development [7]. Hyper-methylation of CGIs
located in the promoter region of a variety of genes implicated in
cell cycle, invasion, apoptosis, DNA repair and drug transport has
been linked to transcriptional silencing of the associated genes
[4,8]. Probably the most prominent gene involved in drug
resistance being transcriptionally regulated via CGI methylation
is ABCB1 (MDR1), encoding the drug efflux transporter P-
glycoprotein. A number of studies have shown that over-
expression of ABCB1 can render cell lines resistant to a wide
range of chemotherapeutic drugs, including doxorubicin [9,10].
However, not only drug transporters but also, genes involved in
metabolizing drugs, repairing the cellular damage caused by them
as well as inducing apoptosis in cells that have been irreparably
damaged play a crucial role in the development of drug resistance,
[11,12].
Based on these considerations, twenty-eight genes whose levels
of expression were previously linked to resistance of different
cancer types to DNA double strand break (DSB) inducing drugs
were selected from literature. Furthermore, each of those genes
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11002was selected to contain one or more CGIs close to its TSS. By
means of microarray hybridization, high-definition methylation
profiles were recorded covering thirty-three CGIs associated with
the twenty-eight selected genes. We used this method to determine
methylation profiles from five carcinoma cell lines representing
two cancer types commonly treated via the DSB inducing
chemotherapeutic drug doxorubicin.
In order to study the effects of acquired doxorubicin resistance
on DNA methylation in breast cancer, we examined methylation
levels in the cell lines MCF-7_wt and MCF-7_ADR. Seeing as
MCF-7_ADR was a doxorubicin selected sub-line of MCF-7_wt,
both cell lines originally exhibited identical genetic as well as
epigenetic backgrounds. Acquired changes in the epigenome of
MCF-7_ADR thus were attributable to the effects of doxorubicin
selection. We further examined CGI methylation levels in the
ovarian carcinoma cell lines OVCAR-4, OVCAR-5 and NCI/
ADR-RES. Unlike MCF-7_wt/_ADR, each of those three cell
lines originated from different patients and therefore exhibited
dissimilar genetic and epigenetic backgrounds. Moreover, OV-
CAR-4 and OVCAR-5 both represented non-doxorubicin
selected cell lines, hence differences in their doxorubicin tolerance
derived from inherent resistance. NCI/ADR-RES, on the other
hand, constituted a doxorubicin selected sub-line originating from
the ovarian carcinoma cell line OVCAR-8 [13] and served as a
model for acquired doxorubicin resistance in ovarian carcinoma.
In detail, the questions addressed by this study were (1) how
does doxorubicin treatment alter DNA methylation in relevant
CGIs in-vitro, (2) how do these changes compare between different
carcinoma cell lines and (3) are detected methylation changes
linked to altered gene expression.
Results
Doxorubicin tolerance of investigated cell lines
For each carcinoma cell line investigated in this study, viability
assays were performed in order to determine their tolerance
against doxorubicin (Figure 1). As expected, IC50 values differed
significantly and documented the cells resistance status.
Detection of CpG methylation levels
We employed microarray technology for the detection of
methylation levels from CpG sites. For that purpose, CGIs of
interest were PCR amplified from sodium bisulfite converted
genomic DNA (gDNA) of each cell line, changing unmethylated
CpG dinucleotides into TpG while leaving methylated ones
unchanged [14]. The exact primer sequences and annealing
temperatures used for PCR amplification are shown in Table S1.
From each sample, pools of labeled PCR-fragments were
hybridized to microarrays containing 25 nucleotide long probe
sequences representing the formerly unmethylated TpG- as well as
methylated CpG-containing sequences. The ratio (CpG/(CpG+
TpG))6100 calculated from both probe signal intensities provided
a measure of the methylation level for each CpG site in percent
[15]. In order to determine the potential of each probe sequence to
detect different levels of methylation from the selected CpG sites,
we hybridized control pools of in-vitro methylated as well as
unmethylated PCR fragments to individual microarrays. Only
probe sequences exhibiting a methylation ratio above 75% for the
fully methylated control, together with less than 25% for the
unmethylated control were considered for subsequent analysis.
The results from two replicates of independently labeled and
hybridized control pools presented in Figure 2A illustrate the high
reproducibility of the method (r
2=0.9879). Figure 2B further gives
an overview of the methylation profiles obtained from three CGIs
associated with the genes DNAJC15, ESR1 and GSTP1 respective-
ly. Cytosine methylation levels from CpG sites within the three
different CGIs presented in Figure 2B were additionally quantified
via sequencing of nine or more sub-cloned PCR products from the
two cell lines MCF-7_wt and MCF-7_ADR. In total, the
methylation levels from 130 CpG sites were determined by means
of microarray hybridization as well as sequencing and revealed a
strong correlation with a coefficient of r
2=0.9258, indicating the
high accuracy of the described method. Methylation profiles
detected via hybridization compared to sequencing analysis are
shown in Figure 2C.
CGI methylation changes linked to acquired doxorubicin
resistance in breast carcinoma cells
We identified CGIs associated with thirteen genes to display
changes in methylation levels between MCF-7_wt and MCF-
7_ADR. Table 1 summarizes the tendencies of methylation
changes between both breast carcinoma cell lines as well as the
three investigated ovarian carcinoma cell lines, with plus (+)
indicating hyper-methylation with acquired doxorubicin resistance
and minus (2) indicating hypo-methylation. CGIs associated with
the genes ABCG2, APAF1, ARHGEF2, AVEN, BAD, BIRC5,
CDKN2A, FANCF, FOXO3A, MLH1, MSH2, PTEN and RALBP1
did not show detectable levels of methylation in any cell line and
hence are not listed in Table 1. Table S2 summarizes the
determined methylation levels from all analyzed CpG sites in each
of the five cell lines.
Overlapping tendencies between breast and ovarian
carcinoma cell lines
When comparing the alterations in methylation levels between
the cell lines MCF-7_wt/_ADR to changes observed in the
ovarian carcinoma cell lines, we found seven CGIs to display the
same tendencies. Specifically, we identified hyper-methylation in
CGIs associated with BRCA1, CDH1, DNAJC15 and SULF2 as well
as hypo-methylation for ABCB1, APC and HIC1 with increased
doxorubicin tolerance (Table 1). Interestingly, the same tendencies
were observed in OVCAR-4 (inherent resistance) as well as in
NCI/ADR-RES (acquired resistance) when compared to OV-
CAR-5. Additionally, we detected hypo-methylation in a CGI
linked to IGFBP3 with increased doxorubicin tolerance, which was
not observed in breast carcinoma cell lines.
Gene expression levels of CGI associated genes
In order to determine the impact of CGI methylation on the
expression of associated genes, we detected mRNA levels of a
subset of genes via qRT-PCR. The normalized results relative to
expression levels in MCF-7_wt are summarized in Table S3.
In the case of the breast carcinoma cell lines MCF-7_wt/_ADR,
the methylation status of CGIs associated with the genes ABCB1,
BRCA1, CDH1, DNAJC15, ESR1, GSTP1, PLAU, SULF2 and
TGM2 was connected to the expression of the genes. This was
assumed to be the case for concomitant mRNA up-regulation after
CGI hypo-methylation as well as mRNA down-regulation after
CGI hyper-methylation. In case of the ovarian carcinoma cell lines
OVCAR-5, OVCAR-4 and NCI/ADR-RES, the methylation
status of CGIs associated with the genes ABCB1, BRCA1, CDH1,
DNAJC15, and SULF2 was connected to the expression of the
genes.
In addition to genes linked to differentially methylated CGIs, we
determined mRNA levels of the gene ABCG2, encoding a putative
doxorubicin efflux transporter [16]. The cell lines most sensitive to
doxorubicin (MCF-7_wt, OVCAR-5) expressed much higher
Doxorubicin Alters Methylation
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7_ADR, OVCAR-4, NCI/ADR-RES). Consequently, ABCG2
expression is not likely to play a significant role in the mechanism
causing resistance in the examined cell lines. We further
determined TOP2A transcript levels; a primary target of
doxorubicin [17,18], and found slightly decreased mRNA levels
in doxorubicin resistant cell lines, which might contribute to their
resistance (Table S3).
Discussion
Comparison of CGI methylation profiles from the breast
carcinoma cell line MCF-7_wt with profiles from its doxorubicin
selected counterpart MCF-7_ADR, allowed us to attribute
changes in methylation levels at specific CpG sites to acquired
doxorubicin resistance. Between both cell lines, we found aberrant
CGI methylation profiles linked to thirteen out of twenty-eight
genes. The identified genes are involved in drug transport and
detoxification (ABCB1 [9,19,20,21,22], DNAJC15 [23,24], GSTP1
[19,21,22], RAB6C [25,26]), DNA damage repair (BRCA1 [27,28])
as well as tumor cell proliferation/invasion (APC [29,30,31], CDH1
[29,32], ESR1 [12,33,34], HIC [29], PLAU [22,35], RASSF1
[29,30,31], SULF2 [36,37], TGM2 [12,38]). An overlapping set of
seven genes (ABCB1, APC, BRCA1, CDH1, DNAJC15, HIC1 and
SULF2) displayed the same methylation changes in the examined
set of ovarian carcinoma cell lines. An overview of methylation
tendencies with acquired doxorubicin resistance is given in
Table 1. For clarity reasons, not all of the identified alterations
are explicitly discussed in the following sections, but rather a
selection of those which illustrate the most important findings of
this study. The full data sets from each analyzed cell line,
consisting of methylation levels from 800 CpG sites as well as the
mRNA levels from a subset of analyzed genes are summarized in
Tables S2 and S3 respectively.
Figure 1. Cell viability after 72 hours of doxorubicin treatment. A: Viability assay of MCF-7_wt and MCF-7_ADR. Dashed line indicates 50
percent viability of untreated control. B: Viability assay of OVCAR-5, OVCAR-4 and NCI/ADR-RES. C: Summary of the determined IC50 values from each
cell line as well as resistance relative to MCF-7_wt (RF).
doi:10.1371/journal.pone.0011002.g001
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CGI sub-regions with increased doxorubicin resistance
An important issue when analyzing DNA methylation levels is
the heterogeneity displayed by many CGIs [39]. While some of the
analyzed islands exhibited almost identical levels of methylation at
each CpG site, some others showed considerable variation in
methylation levels between distinct CGI sub-regions, as was the
case for DNAJC15 and ABCB1 (Figure 3). For that reason, it is
essential to study changes in CGI methylation by means of a
method that allows high-definition analysis. Methylation profiles
from CGIs associated with DNAJC15, a putative inhibitor of
ABCB1 transcription [40], displayed high levels of methylation
between 200 nt upstream and 200 nt downstream from the TSS
in all analyzed cell lines (Figure 3). In the region between 200 nt
and 400 nt downstream from the TSS, however, methylation
levels differed dramatically between sensitive cell lines and cell
lines with acquired doxorubicin resistance. In MCF-7_wt as well
as in OVCAR-5, methylation in the latter region was almost
absent and DNAJC15 mRNA levels were high (Figure 3). In the
more resistant cell lines, the complete CGI was found to be hyper-
methylated and, accordingly, mRNA levels were significantly
lower. These findings were consistent with results from Strathdee
et al. [23], who identified methylation of the same CGI within the
first exon of DNAJC15 to be responsible for the gene’s
transcriptional regulation. Moreover, they linked loss of DNAJC15
expression to resistance to the chemotherapeutic drug cisplatin in
an ovarian carcinoma cell line as well as in ovarian carcinoma
patients [24]. Here we provided additional evidence for the
epigenetic regulation of DNAJC15 expression in breast and
ovarian carcinoma cell lines and further demonstrated the
correlation of the gene’s loss-of-expression with resistance to
doxorubicin.
Moreover, consistent with the proposed inhibitory function of
DNAJC15 on the expression of ABCB1 [40], we found increased
levels of ABCB1 mRNA in cell lines with decreased DNAJC15
levels (Figure 3). One exception, however, was the inherently
resistant cell line OVCAR-4, which exhibited 10-fold decreased
DNAJC15 mRNA levels compared to OVCAR-5, but almost
identical levels of ABCB1. This finding might be explained by
epigenetic silencing of ABCB1 in OVCAR-4, preventing expres-
sion despite reduced levels of its inhibitor DNAJC15. One possible
explanation of the gene’s transcriptional silencing in OVCAR-4
was given by its CGI methylation profile shown in Figure 3. While
CpG sites upstream of 500 nt from the TSS showed no
methylation, downstream CpG sites were highly methylated.
Hence the identified region is of potential relevance for the
epigenetic silencing of ABCB1 expression.
We further identified CGIs linked to the genes ESR1, HIC1,
IGFBP3, SULF2, TGM2 and TP73 to exhibit distinct methylation
sub-regions similar to the ones observed in DNAJC15 and ABCB1
(Table S2). Taken together, these findings highlight the impor-
tance of high-definition profiling for the precise mapping of drug
resistance associated changes of DNA methylation.
CGI associated with GSTP1 becomes partially hypo-
methylated with acquired doxorubicin resistance
The enzyme, glutathione S-transferase P1, encoded by the gene
GSTP1, has long been known to conjugate drugs, including
doxorubicin, with glutathione, resulting in their detoxification
[41]. Its expression has previously been linked to doxorubicin
resistance in ovarian carcinoma cell lines and patients [42,43]. We
found the CGI located within the gene’s first exon to display
continuously high levels of methylation in the doxorubicin
sensitive cell line MCF-7_wt, decreasing to about 50 percent
in MCF-7_ADR (Figure 2B). These findings were confirmed
via clone sequencing (Figure 2C) and thus further illustrate
the presented method’s potential to quantify levels of DNA
methylation.
Seeing as the cell line MCF-7_ADR derived from one single
clone, the existence of two sub-populations, each carrying
exclusively methylated or unmethylated copies of GSTP1 associ-
ated CGIs, is unlikely. A more plausible explanation would be
hypo-methylation of the CGI associated with one of two copies of
GSTP1 during the doxorubicin selection process, while the second
one remained methylated. Concomitantly, GSTP1 mRNA levels in
MCF-7_ADR were strongly increased when compared to MCF-
7_wt, similar to the levels observed in each of the three completely
unmethylated ovarian carcinoma cell lines (Figure 4). These
findings suggest DNA methylation in the CGI of the gene’s first
exon to be involved in the transcriptional regulation of GSTP1.
While GSTP1 mRNA levels are highly different between MCF-
7_ADR and MCF-7_wt; they are largely the same between the
analyzed ovarian carcinoma cell lines. These results argue against
GSTP1 expression levels being a major determinant of doxorubicin
tolerance in OVCAR-5, OVCAR-4 and NCI/ADR-RES.
Figure 2. Methylation profiling – Reproducibility and validation. A: Reproducibility, illustrated via two replicate hybridizations, of fully
methylated and fully unmethylated control fragment pools. B: Methylation profiles determined from CGIs around the TSS of the genes DNAJC15, ESR1
and GSTP1. Shown are hybridizations of fully methylated and unmethylated control fragments as well as fragments amplified from the cell lines MCF-
7_wt and MCF-7_ADR. C: Validation of methylation profiles via clone sequencing of the PCR fragments used for microarray hybridizations shown in
Figure 2B.
doi:10.1371/journal.pone.0011002.g002
Table 1. Tendency of methylation level alterations linked to
doxorubicin resistance.















Hypo-methylation of doxorubicin resistant compared to sensitive cell lines is
indicated by ‘‘minus’’ (2), while hyper-methylation is indicated by ‘‘plus’’
(+).Cells marked with ‘‘none’’ represent CGIs of consistently high or low levels of
methylation between the analyzed cell lines.
doi:10.1371/journal.pone.0011002.t001
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PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11002Figure 3. Hyper- and hypo-methylation events occur in distinct CGI sub-regions with increased doxorubicin resistance. A: A sub-
region of a CGI associated with the gene DNAJC15 becomes hyper-methylated and the gene’s mRNA levels decrease with increased resistance. B:A
sub-region of a CGI associated with the gene ABCB1 becomes hypo-methylated and the gene’s mRNA levels increase with increased resistance.
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of hyper-methylated tumor markers
CGIs associated with three putative tumor suppressor genes
APC, HIC1 and RASSF1 have previously been shown to be
frequently hyper-methylated in breast and ovarian tumors when
compared to healthy tissue [29,30,31]. Furthermore, promoter
hyper-methylation of APC and RASSF1 has been demonstrated to
be a significant prognostic factor for the survival of breast cancer
patients [30]. Accordingly, we detected high levels of CGI
methylation for APC, HIC1 and RASSF1 in the breast carcinoma
cell line MCF-7_wt and for APC and HIC1 in the doxorubicin
sensitive cell line OVCAR-5. Surprisingly, in carcinoma cell lines
of acquired doxorubicin resistance (MCF-7_ADR, NCI/ADR-
RES), methylation of CGIs from APC, HIC1 and RASSF1 was
strongly reduced or completely absent (Table S2). Interestingly,
none of the observed changes in CGI methylation levels were
linked to changes in mRNA levels of the associated genes
(Figure 4). These findings suggest that hypo-methylation of certain
CGIs that typically become hyper-methylated during carcinogen-
esis might be a common event in breast and ovarian carcinoma
cell lines with acquired doxorubicin resistance, but does not lead to
re-expression of associated genes.
Interplay between DNA methylation and chromatin
remodeling
In addition to genes such as APC, HIC1 and RASSF1 which
show altered DNA methylation, but no concomitant change in
gene expression levels we found a number of genes to display
altered gene expression levels but no concomitant change in DNA
methylation. This issue is best illustrated by means of the
examined CGI associated with the gene ABCG2. While no DNA
methylation could be detected in the analyzed region in any of the
cell lines (Table S2), gene expression levels differed significantly
between them (Figure 4). In this respect it is important to keep in
mind that DNA methylation changes on their own do not regulate
gene expression levels, but that this process is tightly coupled to
chromatin modifications such as histone acetylation, methylation
or phosphorylation [44,45]. There is evidence that histone
Methylation profiles from CGIs linked to all analyzed twenty-eight genes are shown in Table S2 and expression levels of a subset of those genes in
Table S3.
doi:10.1371/journal.pone.0011002.g003
Figure 4. Expression levels from a subset of genes. Levels of mRNA from indicated genes in the cell lines MCF-7_wt, MCF-7_ADR, OVCAR-5,
OVCAR-4 and NCI/ADR-RES in logarithmic scale relative to MCF-7_wt. Error bars indicate standard deviation between triplicates. Values are
summarized in Table S3.
doi:10.1371/journal.pone.0011002.g004
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precede DNA methylation changes [5,46]. Hence, in the example
of ABCG2 it is possible that histone modifications influence its
expression independently from DNA methylation in the examined
region.
Breast and ovarian carcinoma cell lines with acquired
doxorubicin resistance display similar methylation
profiles
When we compared methylation levels from all 800 CpG sites
between all breast and ovarian carcinoma cell lines analyzed in
this study, we found methylation profiles from the breast
carcinoma cell line MCF-7_ADR and the ovarian carcinoma cell
line NCI/ADR-RES to be the most similar (Table 2). Given that
both cell lines originated from different cancer types but were
selected for doxorubicin resistance, this finding strongly suggested
similar changes in methylation patterns during formation of
resistance in breast and ovarian carcinoma cells. In comparison,
we found no correlation between profiles from the breast
carcinoma cell line MCF-7_ADR and its parental counterpart
MCF-7_wt (Table 2), further illustrating the profound alterations
of methylation patterns during the acquisition of doxorubicin
resistance.
Conclusions
The detected profiles represent highly accurate comprehensive
pictures of CGI methylation from sets of selected putative drug
resistance genes. Pre-selection of genes allowed the detailed
analysis of methylation profiles from genes of potential relevance
to doxorubicin resistance. It was found that several CGIs exhibited
doxorubicin-related hyper- as well as hypo-methylation only at
specific CpG positions. These findings illustrate the importance of
high-definition profiling as compared to the analysis of only
individual CpG sites.
Materials and Methods
Selection of MCF-7_ADR cells from MCF-7_wt
MCF-7_wt cells were exposed to increasing concentrations of
doxorubicin, initially to 2-fold the IC50 for 24 hours, followed by
washing and incubation in drug-free culture medium until new
colonies had formed. This procedure was repeated several times,
each time doubling the original IC50 up until 64-fold the original
IC50 was reached. Surviving cells were subjected to a doxorubicin
dilution series ranging from 16- to 512-fold the original IC50. Cells
which proliferated at the highest drug concentration within one
week were considered chemotherapy refractory. Resistant colonies
were picked from cells treated with 128-fold the original IC50 and
expanded in continuous presence of 10-fold the original IC50. The
cell line MCF-7_wt and the doxorubicin selected subline MCF-
7_ADR was kindly supplied by the laboratory of Dr. Ralf A.
Hilger. Before the final cell viability assays, cells were cultured in
doxorubicin-free medium for two weeks.
Cell culture conditions and viability assays
MCF-7_wt and MCF-7_ADR cells were cultured in DMEM
(10% FCS, 1% penicillin/streptomycin 10,000 U) and OV-
CAR-5, OVCAR-4 and NCI/ADR-RES cells were obtained
directly from the National Cancer Institute and cultured in
RPMI (10% FCS, 1% penicillin/streptomycin 10,000 U) under
standard cell culture conditions (37uC, 5% CO2). For viability
assays, cells were seeded in triplicate into 96 well microplates at
1,000 as well as 2,000 cells per well. Twenty-four hours later,
cells were treated with different concentrations of doxorubicin.
Seventy-two hours post treatment, cells were incubated with
50 ml medium containing resazurine (20 mg/ml) and incubated
for one to four hours before detection of fluorescence (Ex:
544 nm/Em: 590 nm). After background subtraction, cell
viability from every drug concentration was normalized to the
untreated control.
Amplification and labeling of sample targets
In order to analyze methylation levels from the cell lines of
interest, total genomic DNA (gDNA) was isolated from each cell
line using the QIAamp DNA Micro Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. Following
purification, 2 mg of gDNA from each cell line were subjected to
sodium bisulfite treatment via the EpiTect Bisulfite Kit (Qiagen)
according to the manufacturer’s instructions. Each CGI of interest
was PCR amplified using the primer pair given in Table S1.
Primer pairs were designed using the web-based software
MethPrimer [47] and their optimal annealing temperature was
determined via gradient PCR. The exact sizes of each PCR
product (ranging from 198 nt up to 777 nt in size) as well as
Ensembl transcript IDs and exon IDs from the examined
sequences are summarized in Table S1. Genomic regions of
interest were amplified by means of PCR using 20 ng of purified
sodium bisulfite treated template DNA, 0.4 mM forward and
0.4 mM reverse primer, 250 mM of each dNTP (Fermentas, St.
Leon-Rot, Germany), 16 HotStart Buffer (Qiagen), 16 Q-
Solution (Qiagen), 1.5 mM MgCl2, 2.5 units HotStart polymerase
(Qiagen) and in a total volume of 50 ml. Thermal cycler PCR
conditions were 95uC for 15 min followed by seven cycles of 95uC
for 1:00 min, 64uC for 2:00 min, 72uC for 2:00 min with a
decreased annealing temperature of 1uC in each cycle before an
additional 39 cycles of 95uC for 0:40 min, optimized annealing
temperature (see Table S1) for 2:00 min, 72uC for 1:30 min and
Table 2. Correlation coefficients (r
2) display strongest similarity between methylation profiles from cell lines with acquired
doxorubicin resistance.
MCF-7_ _wt OVCAR-5 OVCAR-4 MCF-7_ _ADR NCI/ADR-RES Cell line
0.0409 0.0239 0.0551 0.0001 MCF-7_ _wt




Shown are correlation coefficients (r
2) between methylation profiles from indicated cell lines. Each methylation profile consists of methylation levels from 800 CpG sites.
doi:10.1371/journal.pone.0011002.t002
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Millipore MultiScreen PCRm96 filter plates according to the
manufacturer’s instructions. For every individual cell line of
interest, equimolar amounts of all purified PCR fragments were
pooled. For labeling, 300 ng from each of those PCR product
pools were incubated together with 30 ng/ml random primer
oligonucleotides (Invitrogen, Karlsruhe, Germany) in a total
volume of 28 mla t9 9 uC for 5 min. After the denaturation step
16 reaction buffer (1 M Hepes pH 6.6, 250 mM Tris-HCl
pH 8.0, 25 mM MgCl2, 50 mM 2-mercaptoethanol), 2 mM of
each dATP, dCTP, dGTP and 1.3 mM dTTP, (Fermentas)
together with 0.7 mM biotinylated-dUTP (Roche, Mannheim,
Germany), 0.4 mg/ml BSA (Sigma, Hamburg, Germany) and 7.5
units Klenow fragment (New England Biolabs, Frankfurt,
Germany) was added to a total volume of 40 ml. After incubation
at 37uC for 3 h and 75uC for 10 min, 4 ml of 3 M sodium acetate
(pH 5.6) and 100 ml ethanol were added and the DNA was
precipitated at 280uC for 2 h. After centrifugation at 18,3206g
for 20 min the supernatant was aspirated, the pellet was dried and
resuspended in 15 ml1 6 hybridization mix (100 mM 2-[N-
morpholino]ethanesulfonic acid (MES), 0.9 M NaCl, 20 mM
Na2EDTA, 0.01% (v/v) Tween-20, 0.5% BSA 0.1 mg/ml herring
sperm DNA (Febit Biomed, Heidelberg, Germany).
Preparation of control targets
From total human gDNA (Invitrogen), fragments containing
each CGI of interest, including the primer binding sites shown in
Table S1, were amplified via PCR. From each fragment, 1 mg was
incubated at 37uC for 3 h together with 8 units of SssI
methyltransferase (NEB, Frankfurt, Germany). To confirm
complete in-vitro methylation 200 ng DNA were digested, using
20 units of the methylation sensitive restriction enzyme BstUI
(NEB) for two hours at 60uC. From each fully methylated as well
as unmethylated target, 1 ng was used for subsequent sodium
bisulfite treatment via the EpiTect Bisulfite Kit (Qiagen) followed
by a PCR amplification step of each CGI. After purification via
QIAquick PCR purification columns (Qiagen), an equimolar pool
of fully methylated as well as one of unmethylated control targets
were prepared. Both pools were labeled and hybridized the same
way as sample target pools.
Microarray analysis
The photo-controlled in-situ synthesis technology Geniom One
(Febit Biomed) was used for synthesis, hybridization and detection
of microarrays [48]. The Geniom One microarray is divided into
eight individually accessible subarrays allowing the analysis of
eight samples in parallel. Probe sequences the size of 25
nucleotides were synthesized, resembling the sodium bisulfite
converted sequence of each CGI of interest. Every probe sequence
was designed to feature at its central position a particular CpG site
of interest either as a CpG or a TpG dinucleotide, hence being
complementary to the methylated (M) or unmethylated (U)
cytosine after sodium bisulfite treatment. Consequently, the
microarray layout included 1600 different probe sequences in
four replicates. Before hybridization the biotinylated target pools
in 16hybridization mix described above, were heated to 95uC for
3 min then placed on ice for 1 min. The denatured targets were
then applied to individual subarrays of the Geniom One
microarray and incubated at 45uC for 16 h. After washing
routines according to the Febit protocol, each subarray was
incubated with 5 mg/ml streptavidin phycoerythrin (Invitrogen) in
66 SSPE (0.9 M NaCl, 60 mM NaH2PO4, pH 7.4 and 6 mM
Na2EDTA). Signal intensity detection was performed using the
inbuilt CCD camera of the system and local backgrounds were
subtracted by means of internal Geniom One software routines.
Finally, signal intensities from probe sequences were used to
determine methylation levels for each CpG site by calculating the
CpG/(CpG+TpG) probe signal intensity ratio, representing the
methylation level M/(M+U). Consequently, a fully methylated
CpG should result in a signal intensity ratio of one whereas a fully
unmethylated CpG should return a value of zero. However, owing
to unspecific cross-hybridization mostly caused by low sequence
complexity of sodium bisulfite treated sequences, not all probe
sequences were suitable for further analysis. In order to identify
probe sequences that could be used to accurately detect
methylation levels from specific CpG sites, in-vitro methylated as
well as unmethylated control pools were used for initial
calibration. The two control pools were hybridized to individual
sub-arrays followed by calculation of M/(M+U) probe signal
intensity ratios for every represented CpG site. In the final
microarray layout, probe sequence pairs were only included when
the hybridization of the fully methylated control pool returned a
probe signal intensity ratio above 0.75 and the hybridization of the
fully unmethylated control pool returned a probe signal intensity
ratio below 0.25.
Clone sequencing
PCR products selected for validation were cloned into pCR4-
TOPO via the TOPO TA cloning kit (Invitrogen) and the
constructs were transformed into TOP10 cells. From each cloned
PCR fragment, twelve different clones were picked and sequenced
(GATC Biotech, Constance, Germany). Final methylation levels
were determined from nine or more sequences obtained from each
PCR fragment.
Quantitative RT-PCR
Total RNA was isolated from each cell line using the RNeasy
Mini Kit (Qiagen) according to the manufacturer’s instructions.
The one-step QuantiFast SYBR Green RT-PCR Kit (Qiagen) was
used in combination with primers from the QuantiTect Primer
Assay (Qiagen). Reactions were performed in 386 well format in
triplicate with 25 ng total RNA per well in a LightCycler 480
(Roche). The endogenous controls ACTB1, GAPDH and
TUBA3C were used for normalization.
Array data deposition
The array data has been deposited with ArrayExpress (http://
www.ebi.ac.uk/microarray-as/ae/) under the accession number
E-MEXP-2698.
Supporting Information
Table S1 Primer sequences for amplification of specified CGIs.
Shown are ENSEMBL transcript and exon IDs used for CGI
definition, as well as primer sequences used for PCR amplification
of the specified CGIs.
Found at: doi:10.1371/journal.pone.0011002.s001 (0.11 MB
PDF)
Table S2 Methylation levels from all analyzed CpG sites.
Methylation levels (M/[M+U])6100 are shown from all CpG
sites of the investigated cell lines MCF-7_wt, MCF-7_ADR,
OVCAR-5, OVCAR-4 and NCI/ADR-RES, together with the
levels obtained from hybridization of 100% methylated, as well as
100% unmethylated, fragment pools. Columns SD show standard
deviations.
Found at: doi:10.1371/journal.pone.0011002.s002 (0.27 MB
XLS)
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expression levels from indicated genes were determined from the
cell lines MCF-7_wt, MCF-7_ADR, OVCAR-5, OVCAR-4 and
NCI/ADR-RES. To allow comparison between cell lines,
expression levels were normalized to a set of house-keeping genes
within each cell line and are presented as fold-changes from MCF-
7_wt. Columns SD show standard deviations from triplicates.
Found at: doi:10.1371/journal.pone.0011002.s003 (0.12 MB
PDF)
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